Pinpointing the minimum and maximum transient noise bandwidth for a transient noise simulation is a non-trivial task. But ...

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

MONTREAL, March 19, 2026 /PRNewswire/ -- Congruence Therapeutics today announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-molecule ...

X-lumin has successfully demonstrated a roundtrip optical transmission from its 15cm Optical Ground Terminal (OGT) to a retroreflector-equipped LEO satellite, and back, with the ability to track ...

Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions ...

ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear ...

At this time, I would like to welcome everyone to the Karyopharm Therapeutics' call to discuss top line results from the Phase III SENTRY trial. There will be a question-and-answer session to follow.

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for ...

Nevertheless, the critical determinant for ciprofloxacin tolerance among genetically distinct persisters is cellular ATP ...

ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy - - ARV-102 was well tolerated across all dose levels following 28 ...

Nanotechnology therapeutics may reshape autoimmune disease care with targeted delivery and immune modulation. Read more.

IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator ...